VistaGen reports positive open-label extension data from PALISADE-4 Phase 3 trial of fasedienol in social anxiety disorder
Bitget2026/09/22 12:35- VistaGen released preliminary positive open-label extension data from the PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder.
- Results were already presented from a July 24, 2026 cut of patients using the nasal spray as needed.
- Safety profile held up with no new drug-related concerns during up to 12 months of real-world, repeated use.
- Exploratory measures showed sustained improvement in social anxiety severity over four months on clinician-rated and patient-reported assessments.
- Management plans an FDA meeting this quarter to discuss a proposed new registrational Phase 3 trial.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After doubling their stock prices this year, Valero Energy (VLO.US) and Marathon Petroleum (MPC.US) have been downgraded by Jefferies: Their valuations are now considered too high.
Jefferies downgraded refiners Valero Energy (VLO.US) and Marathon Petroleum (MPC.US) from "Buy" to "Hold," with target prices of $401 and $413, respectively.
Goldman Sachs Bets on 'Rising Stocks and Bullish Bonds': S&P 500 Targeted at 8,700 Points, 10-Year US Treasury Yield Falls to 4.5%
Goldman Sachs expects the S&P 500 index to rise by 13.7% over the next 12 months, with the 10-year US Treasury yield falling from the current 5% to 4.5%. The bank's 12-month target for the S&P 500 is 8,700 points.
Up 14% since July! Forex options traders bet the Korean won rally will continue
Forex options traders are betting that the Korean won, which has been leading the Asian forex market since July, will continue its strong momentum.
Crypto prices
More
